CVS shareholders approve 2026 incentive plan, re-elect directors at annual meeting

Company proposal to approve the Company’s 2026 Incentive Compensation Plan, as set forth in the Company's Proxy Statement, was approved by the following vote: 1,006,709,390 28,851,289 3,157,795 104,083,932

The election, for one-year terms, of persons nominated for election as directors of the Company, as set forth in the Company’s Proxy Statement, was approved by the following votes: Fernando Aguirre 1,022,555,114 14,973,034 1,190,326 104,083,932 Jeffrey R. Balser, M.D., Ph.D. 1,027,705,454 9,787,711 1,225,309 104,083,932 C. David Brown II 963,381,905 74,082,639 1,253,930 104,083,932 Alecia A. DeCoudreaux 996,234,731 41,326,102 1,157,641 104,083,932 Anne M. Finucane 1,010,527,586 27,032,194 1,158,694 104,083,932 John E. Gallina 1,024,886,453 12,566,628 1,265,393 104,083,932 J. David Joyner 968,110,706 66,554,762 4,053,006 104,083,932 J. Scott Kirby 995,832,249 41,667,652 1,218,573 104,083,932 Michael F. Mahoney 940,279,615 96,450,126 1,988,733 104,083,932 Leslie V. Norwalk 1,021,952,646 15,580,839 1,184,989 104,083,932 Larry M. Robbins 1,026,332,859 11,150,192 1,235,423 104,083,932 Guy P. Sansone 995,433,957 42,056,031 1,228,486 104,083,932 Douglas H. Shulman 1,020,665,806 16,793,215 1,2

Stockholder proposal for reducing the threshold for the Company’s stockholder right to act by written consent, as set forth in the Company’s Proxy Statement, was not approved by the following vote: 417,969,177 617,361,014 3,388,283 104,083,932

Company proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers, as set forth in the Company’s Proxy Statement, was approved by the following vote: 976,252,194 59,088,923 3,377,357 104,083,932

Company proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2026, as set forth in the Company’s Proxy Statement, was approved by the following vote: 1,117,411,640 24,102,167 1,288,599 None